Suchergebnisse - "Janczewska, E"

PubPharm (71)

1

Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients : Epi-Ter2 study

enthalten in: AIDS care | 2020

von Piekarska, A. | Jabłonowska, E. | Garlicki, A. | +29

2

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

enthalten in: The New England journal of medicine | 2020

von Finn, R. | Qin, S. | Ikeda, M. | +119

CommentIn: N Engl J Med. 2020 May 14;382(20):1953-1955. - PMID 32402168

3

Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2019

von Parczewski, M. | Kordek, J. | Janczewska, E. | +12

4

Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study

enthalten in: Journal of viral hepatitis | 2018

von Flisiak, R. | Janczewska, E. | Łucejko, M. | +14

5

Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study

enthalten in: Journal of viral hepatitis | 2018

von Flisiak, R. | Zarębska-Michaluk, D. | Janczewska, E. | +29

6

Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C : AMBER study

enthalten in: Alimentary pharmacology & therapeutics | 2016

von Flisiak, R. | Janczewska, E. | Wawrzynowicz-Syczewska, M. | +26

7

Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

enthalten in: Alimentary pharmacology & therapeutics | 2016

von Flisiak, R. | Janczewska, E. | Wawrzynowicz‐Syczewska, M. | +26

8

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV

enthalten in: The New England journal of medicine | 2014

von Ferenci, P. | Bernstein, D. | Lalezari, J. | +128

CommentIn: N Engl J Med. 2014 May 22;370(21):2043-7. - PMID 24795199

9

P1169 EFFECT OF PEGYLATED INTERFERON OR RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR BASED THERAPY ON SVR12 IN NULL-RESPONDERS AND RELAPSERS WITH ADVANCED LIVER FIBROSIS (ADVEX STUDY)

enthalten in: Journal of hepatology | 2014

von Zarebska-Michaluk, D. | Flisiak, R. | Janczewska, E. | +18

10

P1209 FACTORS INFLUENCING RENAL FUNCTION IN PATIENTS RECEIVING TELAPREVIR TWICE DAILY OR EVERY 8 HOURS: RESULTS FROM THE PHASE III OPTIMIZE STUDY

enthalten in: Journal of hepatology | 2014

von Buti, M. | Agarwal, K. | Horsmans, Y. | +13

1
2
3
4
5
6
7
8
Nächster »
[8]